文献速递胰腺与胆道疾病消化内镜

CT测量的胰腺脂肪变对ERCP后胰腺炎风险的临床影响:一项多中心前瞻性试验

Clinical impact of pancreatic steatosis measured by CT on the risk of post-ERCP pancreatitis: a multicenter prospective trial.
PubMed 文献 · Gastrointest Endosc · 2023-08-18

这项多中心前瞻性试验纳入527例首次接受ERCP且术前接受增强腹部CT的患者,基于平扫CT胰腺衰减评估胰腺脂肪变(PS)。ERCP后24小时,PS组22例(14.0%)发生PEP,无PS组23例(6.2%)发生PEP(P=0.017);PS组PEP风险高于无PS组(OR 2.09,95%CI 1.08-4.03)。结论认为PS是PEP的显著危险因素,应考虑预防措施,并需要标准化的CT测量方案。

要点

  • PS组ERCP后24小时PEP发生率为14.0%(22例),无PS组为6.2%(23例),差异有统计学意义(P=0.017)。
  • PS组发生PEP的风险高于无PS组(OR 2.09,95%CI 1.08-4.03)。
  • PS组糖尿病和高血压较无PS组更常见,血脂异常两组无差异。

核心结论

  • PS是PEP的显著危险因素,应考虑预防措施。
  • 需要标准化的CT测量方案来评估PS。

研究设计与样本

  • 多中心前瞻性试验,纳入786例连续接受增强腹部CT并随后首次ERCP的患者,最终分析527例。
  • PS基于平扫CT图像上的胰腺衰减评估,采用logistic回归模型评估PS对PEP发生的风险。

主要发现

  • 527例中157例(29.8%)有PS,370例(70.2%)无PS。
  • ERCP后24小时,PS组22例(14.0%)发生PEP,无PS组23例(6.2%)发生PEP(P=0.017)。
  • PS组发生PEP的风险高于无PS组(OR 2.09,95%CI 1.08-4.03)。
  • PS组糖尿病和高血压较无PS组更常见,血脂异常两组无差异。
  • 未发现其他变量为PEP的危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Pancreatic steatosis (PS) may be a risk factor for acute pancreatitis. Whether it is also a risk factor for post-ERCP pancreatitis (PEP) has not been evaluated. This study aimed to determine the impact of PS on PEP development. METHODS: This multicenter prospective trial enrolled 786 consecutive patients who underwent contrast-enhanced abdominal CT and subsequent first-time ERCP. PS was evaluated based on pancreatic attenuation on unenhanced CT images. The risk of PS for the development of PEP was evaluated using a logistic regression model. RESULTS: Of 527 patients included in the study, 157 (29.8%) had PS and 370 (70.2%) did not. At 24 hours after ERCP, there was a significant difference in the PEP identified in 22 patients (14.0%) in the PS group and 23 patients (6.2%) in the "no PS" (NPS) group (P = .017). Diabetes and hypertension were more common in the PS group than in the NPS group; no differences in dyslipidemia were found. Patients with PS had a higher risk for the development of PEP than those with NPS (odds ratio, 2.09; 95% confidence interval, 1.08-4.03). No other variables were identified as risk factors for PEP. CONCLUSIONS: PS is a significant risk factor for PEP for which preventive measures should be considered. Standardized measurement protocols to assess PS by CT are needed. (Clinical trial registration number: KCT0006068.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Chung MJ, Park SW, Lee KJ, et al. Clinical impact of pancreatic steatosis measured by CT on the risk of post-ERCP pancreatitis: a multicenter prospective trial. Gastrointest Endosc. 2023. PMID: 37598866. doi:10.1016/j.gie.2023.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。